1.
Abadie J, Hedan B, Cadieu E, et al. Epidemiology, pathology, and genetics of
histiocytic sarcoma in the Bernese mountain dog breed. J Hered. 2009;100
Suppl 1(Suppl 1):S19-27.
2.
Affolter VK, Moore PF. Localized and disseminated histiocytic sarcoma of
dendritic cell origin in dogs. Vet Pathol. 2002;39(1):74-83.
3.
Affolter VK, Moore PF. Feline progressive histiocytosis. Vet Pathol.
2006;43(5):646-655.
4.
Arand J, Sage J. G1 cyclins protect pluripotency. Nat Cell Biol.
2017;19(3):149-150.
5.
Argenta FF, de Britto FC, Pereira PR, et al. Pulmonary Langerhans cell
histiocytosis in cats and a literature review of feline histiocytic diseases. J
Feline Med Surg. 2020;22(4):305-312.
6.
Asada H, Tomiyasu H, Goto-Koshino Y, et al. Evaluation of the drug
sensitivity and expression of 16 drug resistance-related genes in canine
histiocytic sarcoma cell lines. J Vet Med Sci. 2015;77(6):677-684.
7.
Asada H, Tsuboi M, Chambers JK, et al. A 2-base insertion in exon 5 is a
common mutation of the TP53 gene in dogs with histiocytic sarcoma. J Vet
Med Sci. 2017;79(10):1721-1726.
8.
Asada H, Tomiyasu H, Goto-Koshino Y, et al. Effect of a two-base insertion
mutation of the TP53 gene on expression of p53 protein in canine histiocytic
sarcoma cells. Am J Vet Res. 2019;80(7):680-688.
137
9.
Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification
of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-29.
10. Berx G, van Roy F. Involvement of members of the cadherin superfamily in
cancer. Cold Spring Harb Perspect Biol. 2009;1(6):a003129.
11. Boyle EI, Weng S, Gollub J, et al. GO::TermFinder--open source software for
accessing Gene Ontology information and finding significantly enriched Gene
Ontology terms associated with a list of genes. Bioinformatics.
2004;20(18):3710-3715.
12. Busch MD, Reilly CM, Luff JA, et al. Feline pulmonary Langerhans cell
histiocytosis with multiorgan involvement. Vet Pathol. 2008;45(6):816-824.
13. Carpenter PM, Al-Kuran RA, Theuer CP. Paranuaclear E-cadherin in gastric
adenocarcinoma. Am J Clin Pathol. 2002;118(6):887-894.
14. Chakraborty R, Hampton OA, Shen X, Simko SJ, et al. Mutually exclusive
recurrent somatic mutations in MAP2K1 and BRAF support a central role for
ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007-3015.
15. Chatterjee D, Vishwajeet V, Saikia UN, et al. CyclinD1 Is Useful to
Differentiate Langerhans Cell Histiocytosis From Reactive Langerhans Cells.
Am J Dermatopathol. 2019;41(3):188-192.
16. Cheong C, Idoyaga J, Do Y, et al. Production of monoclonal antibodies that
recognize the extracellular domain of mouse langerin/CD207. J Immunol
Methods. 2007;324(1-2):48-62.
17. Coste M, Prata D, Castiglioni V, et al. Feline progressive histiocytosis: a
retrospective investigation of 26 cases and preliminary study of Ki67 as a
prognostic marker. J Vet Diagn Invest. 2019;31(6):801-808.
138
18. Craig LE, Julian ME, Ferracone JD. The diagnosis and prognosis of synovial
tumors in dogs: 35 cases. Vet Pathol. 2002;39(1):66-73.
19. Curran KM, Schaffer PA, Frank CB, et al. BCL2 and MYC are expressed at
high levels in canine diffuse large B-cell lymphoma but are not predictive for
outcome in dogs treated with CHOP chemotherapy. Vet Comp Oncol.
2017;15(4):1269-1279.
20. Dabbs DJ, Kaplai M, Chivukula M, et al. The spectrum of morphomolecular
abnormalities of the E-cadherin/catenin complex in pleomorphic lobular
carcinoma of the breast. Appl Immunohistochem Mol Morphol. 2007;15(3):260266.
21. Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22-35.
22. Davies G, Jiang WG, Mason MD. Matrilysin mediates extracellular cleavage
of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte
growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion.
Clin Cancer Res. 2001;7(10):3289-3297.
23. Dhawan D, Hahn NM, Ramos-Vara JA, et al. Naturally-occurring canine
invasive urothelial carcinoma harbors luminal and basal transcriptional
subtypes found in human muscle invasive bladder cancer. PLoS Genet.
2018;14(8):e1007571.
24. Dobrzycka KM, Kang K, Jiang S, et al. Disruption of scaffold attachment
factor B1 leads to TBX2 up-regulation, lack of p19ARF induction, lack of
senescence, and cell immortalization. Cancer Res. 2006;66(16):7859-7863.
25. Doebel T, Voisin B, Nagao K. Langerhans Cells - The Macrophage in Dendritic
Cell Clothing. Trends Immunol. 2017;38(11):817-828.
139
26. Egeler RM, van Halteren AG, Hogendoorn PC, et al. Langerhans cell
histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage.
Immunol Rev. 2010;234(1):213-232.
27. Erich SA, Constantino-Casas F, Dobson JM, et al. Morphological Distinction of
Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and
Flatcoated Retrievers. In Vivo. 2018;32(1):7-17.
28. Facchetti F, Pileri SA, Lorenzi L, et al. Histiocytic and dendritic cell
neoplasms: what have we learnt by studying 67 cases. Virchows Arch.
2017;471(4):467-489.
29. Ferber EC, Kajita M, Wadlow A, et al. A role for the cleaved cytoplasmic
domain of E-cadherin in the nucleus. J Biol Chem. 2008;283(19):12691-12700.
30. Fidel J, Schiller I, Hauser B, et al. Histiocytic sarcomas in flat-coated
retrievers: a summary of 37 cases (November 1998-March 2005). Vet Comp
Oncol. 2006;4(2):63-74.
31. Fonseca-Alves CE, Rodrigues MM, de Moura VM, et al. Alterations of C-MYC,
NKX3.1, and E-cadherin expression in canine prostate carcinogenesis. Microsc
Res Tech. 2013;76(12):1250-1256.
32. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent
kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor
xenografts. Mol Cancer Ther. 2004;3(11):1427-1438.
33. Gallanis GT, Pericas RI, Riegel AT, et al. An evaluation of palbociclib as a
breast cancer treatment option: a current update. Expert Opin Pharmacother.
2020:1-10.
140
34. Geissmann F, Dieu-Nosjean MC, Dezutter C, et al. Accumulation of immature
Langerhans cells in human lymph nodes draining chronically inflamed skin. J
Exp Med. 2002;196(4):417-430.
35. Geissmann F, Emile JF, Andry P, et al. Lack of expression of E-cadherin is
associated with dissemination of Langerhans' cell histiocytosis and poor
outcome. J Pathol. 1997;181(3):301-304.
36. Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans
cells in Langerhans cell histiocytosis. Blood. 2001;97(5):1241-1248.
37. Giantin M, Granato A, Baratto C, et al. Global gene expression analysis of
canine cutaneous mast cell tumor: could molecular profiling be useful for
subtype classification and prognostication?. PLoS One. 2014;9(4):e95481.
38. Ginhoux F, Tacke F, Angeli V, et al. Langerhans cells arise from monocytes in
vivo. Nat Immunol. 2006;7(3):265-273.
39. Gomez-Escudero J, Moreno V, Martin-Alonso M, et al. E-cadherin cleavage by
MT2-MMP regulates apical junctional signaling and epithelial homeostasis in
the intestine. J Cell Sci. 2017;130(23):4013-4027.
40. Grace SA, Sutton AM, Armbrecht ES, et al. p53 Is a Helpful Marker in
Distinguishing Langerhans Cell Histiocytosis From Langerhans Cell
Hyperplasia. Am J Dermatopathol. 2017;39(10):726-730.
41. Hazim AZ, Ruan GJ, Ravindran A, et al. Efficacy of BRAF-Inhibitor Therapy
in BRAF(V600E) -Mutated Adult Langerhans Cell Histiocytosis. Oncologist.
2020. doi:10.1002/onco.13541.
42. Hedan B, Thomas R, Motsinger-Reif A, et al. Molecular cytogenetic
characterization of canine histiocytic sarcoma: A spontaneous model for
human histiocytic cancer identifies deletion of tumor suppressor genes and
141
highlights influence of genetic background on tumor behavior. BMC Cancer.
2011;11:201-2407-11-201.
43. Hedan B, Rault M, Abadie J, et al. PTPN11 mutations in canine and human
disseminated histiocytic sarcoma. Int J Cancer. 2020;15;147(6):1657-1665.
44. Heisig A, Sorensen J, Zimmermann SY, et al. Vemurafenib in Langerhans cell
histiocytosis: report of a pediatric patient and review of the literature.
Oncotarget. 2018;9(31):22236-22240.
45. Hu W, Sung T, Jessen BA, et al. Mechanistic Investigation of Bone Marrow
Suppression Associated with Palbociclib and its Differentiation from Cytotoxic
Chemotherapies. Clin Cancer Res. 2016;22(8):2000-2008.
46. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists.
Nucleic Acids Res. 2009;37(1):1-13.
47. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis
of large gene lists using DAVID bioinformatics resources. Nat Protoc.
2009;4(1):44-57.
48. Ide K, Setoguchi-Mukai A, Nakagawa T, et al. Disseminated histiocytic
sarcoma with excessive hemophagocytosis in a cat. J Vet Med Sci.
2009;71(6):817-820.
49. Ide T, Uchida K, Tamura S, et al. Histiocytic sarcoma in the brain of a cat. J
Vet Med Sci. 2010;72(1):99-102.
50. Iorfida M, Mazza M, Munzone E. Fulvestrant in Combination with CDK4/6
Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives. Breast
Cancer (Dove Med Press). 2020;12:45-56.
142
51. Ito K, Kuroki S, Kobayashi M, et al. Identification of dasatinib as an in vitro
potent growth inhibitor of canine histiocytic sarcoma cells. Vet J.
2013;196(3):536-540.
52. Jakob T, Ring J, Udey MC. Multistep navigation of Langerhans/dendritic cells
in and out of the skin. J Allergy Clin Immunol. 2001;108(5):688-696.
53. Jensen MM, Jorgensen JT, Binderup T, et al. Tumor volume in subcutaneous
mouse xenografts measured by microCT is more accurate and reproducible
than determined by 18F-FDG-microPET or external caliper. BMC Med
Imaging. 2008;8:16-2342-8-16.
54. Johnson SK, Ramani VC, Hennings L, et al. Kallikrein 7 enhances pancreatic
cancer cell invasion by shedding E-cadherin. Cancer. 2007;109(9):1811-1820.
55. Kaplan DH. Ontogeny and function of murine epidermal Langerhans cells.
Nat Immunol. 2017;18(10):1068-1075.
56. Klucky B, Mueller R, Vogt I, et al. Kallikrein 6 induces E-cadherin shedding
and promotes cell proliferation, migration, and invasion. Cancer Res.
2007;67(17):8198-8206.
57. Kobayashi M, Kuroki S, Ito K, et al. Imatinib-associated tumour response in a
dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit
exon 11 deletion mutation. Vet J. 2013;198(1):271-274.
58. Kommalapati A, Tella SH, Durkin M, et al. Histiocytic sarcoma: a populationbased analysis of incidence, demographic disparities, and long-term outcomes.
Blood. 2018;131(2):265-268.
59. Kordes M, Röring M, Heining C, et al. Cooperation of BRAF(F595L) and
mutant HRAS in histiocytic sarcoma provides new insights into oncogenic
BRAF signaling. Leukemia. 2016;30(4):937-946.
143
60. Kraje AC, Patton CS, Edwards DF. Malignant histiocytosis in 3 cats. J Vet
Intern Med. 2001;15(3):252-256.
61. Kwon JS, Everetts NJ, Wang X, et al. Controlling Depth of Cellular
Quiescence by an Rb-E2F Network Switch. Cell Rep. 2017;20(13):3223-3235.
62. Larregina AT, Morelli AE, Spencer LA, et al. Dermal-resident CD14+ cells
differentiate into Langerhans cells. Nat Immunol. 2001;2(12):1151-1158.
63. Li L, Wu D, Yu Q, et al. Prognostic value of FOXM1 in solid tumors: a
systematic review and meta-analysis. Oncotarget. 2017;8(19):32298-32308.
64. Liao GB, Li XZ, Zeng S, et al. Regulation of the master regulator FOXM1 in
cancer. Cell Commun Signal. 2018;16(1):57-018-0266-6.
65. Liao X, Hong Y, Mao Y, et al. SPH3643: A novel cyclin-dependent kinase 4/6
inhibitor with good anticancer efficacy and strong blood-brain barrier
permeability. Cancer Sci. 2020;111(5):1761-1773.
66. Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells
with elevated c-Myc. Cell. 2012;151(1):56-67.
67. Liu Q, Tomaszewicz K, Hutchinson L, et al. Somatic mutations in histiocytic
sarcoma identified by next generation sequencing. Virchows Arch.
2016;469(2):233-241.
68. Lopes RA, Cardoso TC, Luvizotto MC, et al. Occurrence and expression of p53
suppressor gene and c-Myc oncogene in dog eyelid tumors. Vet Ophthalmol.
2010;13(2):69-75.
69. Maeda S, Tomiyasu H, Tsuboi M, et al. Comprehensive gene expression
analysis of canine invasive urothelial bladder carcinoma by RNA-Seq. BMC
Cancer. 2018;18(1):472-018-4409-3.
144
70. Marconato L, Sabattini S, Buchholz J, et al. Outcome comparison between
radiation therapy and surgery as primary treatment for dogs with
periarticular histiocytic sarcoma: An Italian Society of Veterinary Oncology
study. Vet Comp Oncol. 2020;18(4):778-786.
71. Mareel MM, Behrens J, Birchmeier W, et al. Down-regulation of E-cadherin
expression in Madin Darby canine kidney (MDCK) cells inside tumors of nude
mice. Int J Cancer. 1991;47(6):922-928.
72. McGinnis LM, Nybakken G, Ma L, et al. Frequency of MAP2K1, TP53, and
U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further
Characterizing the Genomic Landscape of LCH. Am J Surg Pathol.
2018;42(7):885-890.
73. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of
Langerhans cells and other langerin-expressing dendritic cells. Nat Rev
Immunol. 2008;8(12):935-947.
74. Milne P, Bigley V, Gunawan M, et al. CD1c+ blood dendritic cells have
Langerhans cell potential. Blood. 2015;125(3):470-473.
75. Moore PF. A review of histiocytic diseases of dogs and cats. Vet Pathol.
2014;51(1):167-184.
76. Moore PF. Canine and Feline Histiocytic Diseases. In: Meuten DJ, ed. Tumors
in Domestic Animals. 5th ed. Ames, IA: Blackwell; 2017: 322-336.
77. Moore AS, Taylor DP, Reppas G, et al. Chemotherapy for dogs with lymph
node metastasis from histiocytic sarcomas. Aust Vet J. 2017;95(1-2):37-40.
78. Nakamine H, Yamakawa M, Yoshino T, et al. Langerhans Cell Histiocytosis
and Langerhans Cell Sarcoma: Current Understanding and Differential
Diagnosis. J Clin Exp Hematop. 2016;56(2):109-118.
145
79. Otsuka M, Egawa G, Kabashima K. Uncovering the mysteries of Langerhans
cells, inflammatory dendritic epidermal cells, and monocyte-derived
Langerhans cell-like cells in the epidermis. Front Immunol. 2018;9:1768.
80. Paredes J, Figueiredo J, Albergaria A, et al. Epithelial E- and P-cadherins:
role and clinical significance in cancer. Biochim Biophys Acta.
2012;1826(2):297-311.
81. Paterson S, Boydell P, Pike R. Systemic histiocytosis in the Bernese mountain
dog. J Small Anim Pract. 1995;36(5):233-236.
82. Pazdzior-Czapula K, Rotkiewicz T, Otrocka-Domagała I, et al. Morphology and
immunophenotype of canine cutaneous histiocytic tumours with particular
emphasis on diagnostic application. Vet Res Commun. 2015;39(1):7-17.
83. Pinard J, Wagg CR, Girard C, et al. Histiocytic sarcoma in the tarsus of a cat.
Vet Pathol. 2006;43(6):1014-1017.
84. Pinto da Cunha N, Ghisleni G, Scarampella F, et al. Cytologic and
immunocytochemical characterization of feline progressive histiocytosis. Vet
Clin Pathol. 2014;43(3):428-436.
85. Ramos-Vara JA, Miller MA. Immunohistochemical expression of E-cadherin
does not distinguish canine cutaneous histiocytoma from other canine round
cell tumors. Vet Pathol. 2011;48(3):758-763.
86. Rassnick KM, Moore AS, Russell DS, et al. Phase II, open-label trial of singleagent CCNU in dogs with previously untreated histiocytic sarcoma. J Vet
Intern Med. 2010;24(6):1528-1531.
87. Santifort KM, Jurgens B, Grinwis GC, et al. Invasive nasal histiocytic
sarcoma as a cause of temporal lobe epilepsy in a cat. JFMS Open Rep.
2018;4(2):2055116918811179.
146
88. Schoos A, Knab VM, Gabriel C, et al. In vitro study to assess the efficacy of
CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary
tumours. Vet Comp Oncol. 2019;17(4):507-521.
89. Scurrell E, Trott A, Rozmanec M, et al. Ocular histiocytic sarcoma in a cat. Vet
Ophthalmol. 2013;16 Suppl 1:173-176.
90. Shanmugam V, Griffin GK, Jacobsen ED, et al. Identification of diverse
activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. Mod
Pathol. 2019;32(6):830-843.
91. Shimono J, Miyoshi H, Arakawa F, et al. Prognostic factors for histiocytic and
dendritic cell neoplasms. Oncotarget. 2017;8(58):98723-98732.
92. Skorupski KA, Rodriguez CO, Krick EL, et al. Long-term survival in dogs with
localized histiocytic sarcoma treated with CCNU as an adjuvant to local
therapy. Vet Comp Oncol. 2009;7(2):139-144.
93. Skorupski KA, Clifford CA, Paoloni MC, et al. CCNU for the treatment of dogs
with histiocytic sarcoma. J Vet Intern Med. 2007;21(1):121-126.
94. Son NV, Uchida K, Thongtharb A, et al. Establishment of cell line and in vivo
mouse model of canine Langerhans cell histiocytosis. Vet Comp Oncol.
2019;17(3):345-353.
95. Stoitzner P, Tripp CH, Douillard P, et al. Migratory Langerhans cells in
mouse lymph nodes in steady state and inflammation. J Invest Dermatol.
2005;125(1):116-125.
96. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2017.
97. Takada M, Hix JML, Corner S, et al. Targeting MEK in a Translational Model
of Histiocytic Sarcoma. Mol Cancer Ther. 2018;17(11):2439-2450.
147
98. Takada M, Parys M, Gregory-Bryson E, et al. A novel canine histiocytic
sarcoma cell line: initial characterization and utilization for drug screening
studies. BMC Cancer. 2018;18(1):237-018-4132-0.
99. Takada M, Smyth LA, Thaiwong T, et al. Activating Mutations in PTPN11
and KRAS in Canine Histiocytic Sarcomas. Genes (Basel). 2019;10(7):505. doi:
10.3390/genes10070505.
100. Takahashi M, Tomiyasu H, Hotta E, et al. Clinical characteristics and
prognostic factors in dogs with histiocytic sarcomas in Japan. J Vet Med Sci.
2014;76(5):661-666.
101. Tomokiyo R, Jinnouchi K, Honda M, et al. Production, characterization, and
interspecies reactivities of monoclonal antibodies against human class A
macrophage scavenger receptors. Atherosclerosis. 2002;161(1):123-132.
102. Thongtharb A, Uchida K, Chambers JK, et al. Histological and
immunohistochemical studies on primary intracranial canine histiocytic
sarcomas. J Vet Med Sci. 2016;78(4):593-599.
103. Thongtharb A, Uchida K, Chambers JK, et al. Variations in histiocytic
differentiation of cell lines from canine cerebral and articular histiocytic
sarcomas. Vet Pathol. 2017;54(3):395-404.
104. Tzankov A, Kremer M, Leguit R, et al. Histiocytic cell neoplasms involving the
bone marrow: summary of the workshop cases submitted to the 18th meeting
of the European Association for Haematopathology (EAHP) organized by the
European Bone Marrow Working Group, Basel 2016. Ann Hematol.
2018;97(11):2117-2128.
105. Vormer TL, Foijer F, Wielders CL, et al. Anchorage-independent growth of
pocket protein-deficient murine fibroblasts requires bypass of G2 arrest and
148
can be accomplished by expression of TBX2. Mol Cell Biol. 2008;28(24):72637273.
106. Wansleben S, Peres J, Hare S, et al. T-box transcription factors in cancer
biology. Biochim Biophys Acta. 2014;1846(2):380-391.
107. Wong SHM, Fang CM, Chuah LH, et al. E-cadherin: its dysregulation in
carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018;121:1122.
108. Wong VM, Snyman HN, Ackerley C, et al. Primary nasal histiocytic sarcoma
of macrophage-myeloid cell type in a cat. J Comp Pathol. 2012;147(2-3):209213.
109. Yamada O, Kobayashi M, Sugisaki O, et al. Imatinib elicited a favorable
response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation
via suppression of constitutive KIT activation. Vet Immunol Immunopathol.
2011;142(1-2):101-106.
110. Yamate J, Yoshida H, Tsukamoto Y, et al. Distribution of cells
immunopositive for AM-3K, a novel monoclonal antibody recognizing human
macrophages, in normal and diseased tissues of dogs, cats, horses, cattle, pigs,
and rabbits. Vet Pathol. 2000;37(2):168-176.
111. Yamazaki H, Takagi S, Hosoya K, et al. Survivin suppressor (YM155)
enhances chemotherapeutic efficacy against canine histiocytic sarcoma in
murine transplantation models. Res Vet Sci. 2015;99:137-144.
112. Zainal NS, Lee BKB, Wong ZW, et al. Effects of palbociclib on oral squamous
cell carcinoma and the role of PIK3CA in conferring resistance. Cancer Biol
Med. 2019;16(2):264-275.
149
...
論文の公開元へ
